Novartis Bolsters Cancer Portfolio with Major $3 Billion Acquisition
Novartis, Bolsters
21.03.2026 – 05:57:11 | boerse-global.de
Novartis acquires PI3K-alpha inhibitor SNV4818 in a…
Novartis’ Bold Move: Acquiring Potential Game-Changer in Breast Cancer Treatment
In a significant move within the pharmaceutical sector, Novartis has struck a deal to acquire SNV4818, a…